Meridian Bioscience Stock

Meridian Bioscience Equity Turnover

The Equity Turnover of Meridian Bioscience (VIVO) as of Aug 7, 2026 is 0.90. In the previous year, Equity Turnover was 0.97 — a change of -6.56% (lower).

Equity Turnover

0.90

YoY

-6.56%

Last updated:

Equity Turnover of Meridian Bioscience is 2026 0.90 . Equity Turnover of Meridian Bioscience was 2025 0.97 . It decreases by -6.56% lower compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Equity Turnover of Meridian Bioscience is 0.90 in 2026.

Equity Turnover of Meridian Bioscience changed from 0.97 to 0.90, representing a -6.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API
Get Free API Key

Profitability — Meridian Bioscience

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Meridian Bioscience